Investing
Top Analyst Upgrades and Downgrades: Ally, Corning, Enterprise, Kinder Morgan, Twitter, Aerie Pharma and More
June 16, 2015 8:40 am
Last Updated: June 16, 2015 8:40 am
Stocks were lower again on Tuesday, but off the lows as worries of the Greek situation may be overblown. The one constant trend over the past three and a half years is that investors buy every pullback. 24/7 Wall St. reviews dozens of analyst and brokerage research reports each morning of the week. The goal is to find value and upside, or new trading and investing ideas for our readers. Some analyst calls cover stocks to buy, while other calls are about stocks to sell or avoid.
Source: Jon Ogg
These are this Tuesday’s top analyst upgrades, downgrades and initiations.
Ally Financial Inc. (NYSE: ALLY) was raised to Buy from Neutral with a $27.00 price target (versus a $22.85 close) at Goldman Sachs. Ally has a consensus price target of $26.63 and a 52-week trading range of $19.42 to $25.14.
Corning Inc. (NYSE: GLW) was raised to Outperform from Sector Perform with a price target of $26.00 (versus a $20.38 close) at RBC Capital Markets. Corning has a $23.97 consensus price target and a 52-week range of $17.03 to $25.16.
Enterprise Product Partners L.P. (NYSE: EPD) was started as Buy with a price target of $39.00 (versus a $32.01 close) at SunTrust. Enterprise has a consensus price target of $40.39 and a 52-week high of $41.38.
Kinder Morgan Inc. (NYSE: KMI) was started as Buy with a price target of $48.00 (versus a $39.36 close) at SunTrust. Kinder Morgan has a consensus price target of $47.76 and a 52-week range of $33.25 to $44.71.
Twitter Inc. (NYSE: TWTR) was downgraded to Neutral from Buy with a price target of $39.00 (versus a $34.67 close) at MKM Partners. The firm sees no near-term catalysts for short-term improvements. 24/7 Wall St. just offered a fresh view of how analysts see Twitter after the Costolo resignation news.
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) shares were up more than 50% after positive FDA news about changing its primary endpoint of Rhopressa. Needham raised its rating to Buy from Hold with a $27.00 price target (versus a $13.27 close and a $20.75 premarket level).
ALSO READ: 6 Analyst Stocks Called to Rise 50% to 100%
Following are additional analyst upgrades, downgrades and initiations seen Tuesday morning:
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Editors' Picks
